Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for MAPK inhibitor
Most Correlated Studies
- Monocyte-derived dendritic cells treated with MEK inhibitor U0126 or p38/MAPK inhibitor SB203580
- MDCK cells treated with hepatocyte growth factor and MAPK ERK pathway inhibitors
- Breast adenocarcinoma MCF7 cells treated with estrogen in presence of MAPK or mTOR inhibitor
- Lungs of mice with TGF-alpha induced fibrosis, treated with MAPK (ARRY) and PI3K (PX-886) inhibitors
- Pulmonary Hypertension in a Rodent Model 1
Most Relevant Literature
- A patent review of MAPK inhibitors (2018 - present).
- Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic …
- Design, Synthesis, and Molecular Docking of Novel Miscellaneous Chalcones as p38α Mitogen-Activated …
- The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein k…
- Design, Synthesis, and Biological Characterization of Inhaled p38α/β MAPK Inhibitors for the Treatme…
Most Relevant Clinical Trials
- Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses
- Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild …
- JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathw…
- p38 Mitogen−Activated Protein Kinase (MAPK) and Steroid Insensitivity in Asthma
- MAPK Inhibition Combined with Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
